newsfilter
← Latest News
GlobeNewswire·

CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and